UCB (OTCMKTS:UCBJY) Upgraded by Jefferies Financial Group to “Moderate Sell” Rating

Jefferies Financial Group upgraded shares of UCB (OTCMKTS:UCBJY) to a moderate sell rating in a research note released on Monday,Zacks.com reports.

Other analysts also recently issued reports about the stock. Wolfe Research upgraded shares of UCB to a “strong-buy” rating in a report on Monday, February 23rd. Zacks Research downgraded shares of UCB from a “hold” rating to a “strong sell” rating in a research report on Thursday, June 11th. Finally, Barclays downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold”.

UCB Price Performance

Shares of UCBJY opened at $143.03 on Monday. The company has a current ratio of 1.38, a quick ratio of 1.04 and a debt-to-equity ratio of 0.20. The stock has a 50 day simple moving average of $144.16 and a 200 day simple moving average of $147.52. UCB has a 52-week low of $94.75 and a 52-week high of $168.76.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.